Cision PR Newswire, Author at World Lifestyler

No Result

View All Result

WORLD LIFESTYLER

No Result

View All Result

Home Author

Cision PR Newswire

Press Releases - Lifestyle

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

June 5, 2026

Press Releases - Lifestyle

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

June 5, 2026

Press Releases - Lifestyle

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

June 5, 2026

Press Releases - Lifestyle

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

June 5, 2026

Press Releases

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

June 5, 2026

Press Releases - Food & Drink

Corner Bakery Offers $50 Off Catering for Game-Day Watch Parties

June 5, 2026

Press Releases - Lifestyle

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

June 5, 2026

Press Releases - Lifestyle

BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit

June 5, 2026

Press Releases - Lifestyle

Europe’s competitiveness hinges on integrated industrial electrification, new Eurelectric report shows

June 5, 2026

Press Releases

Corgi Launches Suite of Six Fixed Income ETFs on Cboe BZX, Capping a Week of 50 Fund Launches

June 5, 2026

Page 748 of 3653 Prev 1 … 747 748 749 … 3,653 Next

No Result

View All Result

Home

Cision PR Newswire

Machine Learning Model Accurately Predicts Long-Term Risk of Type 2 Diabetes

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

Ambrosia Biosciences Announces Preclinical Data Supporting Differentiated Profile of AMB-702, its Novel Small Molecule GLP-1 Receptor Agonist Development Candidate

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Corner Bakery Offers $50 Off Catering for Game-Day Watch Parties

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

BMI Investors Have Opportunity to Lead Badger Meter, Inc. Securities Fraud Lawsuit

Europe’s competitiveness hinges on integrated industrial electrification, new Eurelectric report shows

Corgi Launches Suite of Six Fixed Income ETFs on Cboe BZX, Capping a Week of 50 Fund Launches

Recommended

Inspire Surpasses $4 Billion in Assets Under Management

NEW INDEPENDENT STUDY FROM DNA&STONE’S CSO FINDS PERSISTENT GENDER PAY GAP IN U.S. ADVERTISING INDUSTRY

Popular News

Parkspring Multifamily Celebrates Grand Opening of The Lucille Waco

Finding Calm in the Roar: Hisense Creates More Inclusive FIFA World Cup 2026™ Experiences for Fans Across All 16 Host Cities

BASEBALL’S GRADY EMERSON AND SOCCER’S MADDIE DIMARIA NAMED GATORADE BEST PLAYERS OF THE YEAR

China-CEEC trade rises 11% in first half, customs data shows

Clinicians Are Adopting AI to Solve the Documentation Crisis, New Global Survey Finds

Connect with us

About & Contact

Explore Content

Legal & Privacy

Tiny Media Brands